Freestone Grove Partners’s AbbVie ABBV Stock Holding History

Freestone Grove Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$435	Buy	+2	New	+$444	﹤0.01%	888
2025 Q4	–	Sell	-294,201	Closed	-$68.1M	–	716
2025 Q3	$68.1M	Buy	294,201 +12,893	+5%	+$2.63M	0.51%	47
2025 Q2	$52.2M	Buy	+281,308	New	+$52.3M	0.39%	88
2025 Q1	–	Sell	-7,601	Closed	-$1.35M	–	571
2024 Q4	$1.35M	Buy	+7,601	New	+$1.4M	0.02%	282

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Freestone Grove Partners's ABBV Position: Q1 2026 in Review

Freestone Grove Partners opened a new position in AbbVie (ABBV) in Q1 2026: 2 shares worth $435. The stake represents ﹤0.01% of the portfolio and ranks #888 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in ABBV as recently as Q3 2025.

Freestone Grove Partners first reported a position in ABBV in Q4 2024 and has held it in 4 quarters since. The position peaked at $68.1M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Freestone Grove Partners held 2 shares of AbbVie worth $435 as of Q1 2026.
AbbVie was a new Freestone Grove Partners position in Q1 2026.
AbbVie made up ﹤0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #888 holding.
Freestone Grove Partners first reported a position in AbbVie in Q4 2024 and has held it in 4 quarters since.
Freestone Grove Partners's AbbVie position peaked at $68.1M in Q3 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.